Index | RUT |
P/E | - |
EPS (ttm) | -3.47 |
Insider Own | 43.97% |
Shs Outstand | 38.28M |
Perf Week | -1.38% |
Market Cap | 493.48M |
Forward P/E | - |
EPS next Y | -3.61 |
Insider Trans | -1.43% |
Shs Float | 21.45M |
Perf Month | 8.05% |
Enterprise Value | 248.05M |
PEG | - |
EPS next Q | -1.04 |
Inst Own | 46.45% |
| |
Perf Quarter | 17.18% |
Income | -143.75M |
P/S | 19.41 |
EPS this Y | -14.76% |
Inst Trans | -13.10% |
| |
Perf Half Y | 88.73% |
Sales | 25.42M |
P/B | 1.61 |
EPS next Y | 9.28% |
ROA | -31.81% |
| |
Perf YTD | 25.39% |
Book/sh | 8.00 |
P/C | 1.67 |
EPS next 5Y | 0.10% |
ROE | -39.13% |
52W High | 14.49 -11.04% |
Perf Year | 45.32% |
Cash/sh | 7.74 |
P/FCF | - |
EPS past 3/5Y | -4.74% -32.56% |
ROIC | -40.73% |
52W Low | 4.93 161.46% |
Perf 3Y | 10.08% |
Dividend Est. | - |
EV/EBITDA | - |
Sales past 3/5Y | - - |
Gross Margin | 83.75% |
Volatility | 4.93% 5.36% |
Perf 5Y | - |
Dividend TTM | - |
EV/Sales | 9.76 |
EPS Y/Y TTM | -274.08% |
Oper. Margin | -613.66% |
ATR (14) | 0.69 |
Perf 10Y | - |
Dividend Ex-Date | - |
Quick Ratio | 12.53 |
Sales Y/Y TTM | -87.94% |
Profit Margin | -565.48% |
RSI (14) | 48.28 |
| |
Dividend Gr. 3/5Y | - - |
Current Ratio | 12.53 |
EPS Q/Q | -3679.47% |
SMA20 | -4.26% |
Beta | -0.12 |
| |
Payout | - |
Debt/Eq | 0.17 |
Sales Q/Q | -96.53% |
SMA50 | 2.25% |
Rel Volume | 0.71 |
Prev Close | 12.96 |
Employees | 152 |
LT Debt/Eq | 0.15 |
| |
SMA200 | 42.20% |
Avg Volume | 194.95K |
Price | 12.89 |
IPO | Oct 29, 2021 |
Option/Short | Yes / Yes |
| |
Trades | |
Volume | 138,060 |
Change | -0.54% |
|
 |
|
|
|
| |
| Date |
Action |
Analyst |
Rating Change |
Price Target Change |
| Apr-01-26 | Initiated |
Cantor Fitzgerald |
Overweight |
|
| Feb-11-26 | Initiated |
Guggenheim |
Buy |
$20 |
| Jan-28-26 | Initiated |
Oppenheimer |
Outperform |
$21 |
| Dec-06-24 | Initiated |
ROTH MKM |
Buy |
$29 |
| Jan-05-24 | Initiated |
Oppenheimer |
Outperform |
$22 |
| Apr-03-23 | Initiated |
H.C. Wainwright |
Buy |
$25 |
|
|
|
Mar-02-26 04:30PM
|
|
|
Feb-26-26 07:00AM
|
|
|
Feb-25-26 07:25PM
|
|
|
Feb-24-26 09:40AM
|
|
|
Feb-19-26 10:00AM
|
|
| 07:58AM |
Loading… |
|
Feb-18-26 07:58AM
|
|
|
Feb-17-26 07:00AM
|
|
|
Feb-15-26 03:02PM
|
|
|
Feb-05-26 06:00PM
|
|
|
Feb-04-26 07:40AM
|
|
|
07:00AM
|
|
|
Jan-09-26 07:16AM
|
|
|
Jan-08-26 07:00AM
|
|
|
Dec-30-25 08:45AM
|
|
|
Dec-17-25 07:00AM
|
|
| 04:30PM |
Loading… |
|
Dec-04-25 04:30PM
|
|
|
Nov-06-25 08:30AM
|
|
|
07:00AM
|
|
|
Oct-30-25 08:10AM
|
|
|
Oct-29-25 07:46AM
|
|
|
Oct-28-25 07:00AM
|
|
|
Sep-05-25 07:00AM
|
|
|
Sep-02-25 04:30PM
|
|
|
Aug-06-25 08:15AM
|
|
|
07:00AM
|
|
|
Jul-31-25 10:15AM
|
|
|
Jun-03-25 07:00AM
|
|
|
Jun-02-25 04:30PM
|
|
|
May-29-25 11:10AM
|
|
|
May-28-25 07:00AM
|
|
| 08:15AM |
Loading… |
|
May-08-25 08:15AM
|
|
|
07:00AM
|
|
|
May-01-25 10:01AM
|
|
|
08:00AM
|
|
|
Apr-29-25 10:01AM
|
|
|
Apr-10-25 09:30AM
|
|
|
Mar-26-25 10:17AM
|
|
|
Mar-25-25 10:03AM
|
(Clinical Trials Arena)
-5.79%
|
|
Mar-24-25 07:00AM
|
|
|
Feb-27-25 08:25AM
|
|
|
07:00AM
|
|
|
Feb-26-25 06:11AM
|
|
|
Feb-25-25 01:05PM
|
(Clinical Trials Arena)
-5.68%
|
|
Feb-24-25 07:00AM
|
|
|
Feb-12-25 07:58AM
|
|
|
Feb-04-25 07:19AM
|
|
|
Feb-03-25 07:00AM
|
|
|
Jan-30-25 04:05PM
|
|
|
Dec-18-24 07:00AM
|
|
|
Dec-07-24 05:25AM
|
|
|
Nov-25-24 08:50AM
|
|
|
Nov-05-24 08:15AM
|
|
|
07:00AM
|
|
|
Oct-09-24 07:00AM
|
|
|
Sep-24-24 07:00AM
|
|
|
Sep-17-24 08:30AM
|
|
|
Sep-06-24 07:00AM
|
|
|
Aug-13-24 08:20AM
|
|
|
07:00AM
|
|
|
Jul-25-24 09:55AM
|
|
|
Jul-12-24 09:33AM
|
|
|
Jun-24-24 07:15AM
|
|
|
06:00AM
|
|
|
Jun-03-24 07:00AM
|
|
|
May-21-24 09:55AM
|
|
|
May-20-24 05:32PM
|
|
|
May-16-24 07:02PM
|
|
|
04:35PM
|
|
|
07:00AM
|
|
|
May-07-24 01:53PM
|
|
|
07:00AM
|
|
|
Apr-10-24 03:29PM
|
|
|
Apr-04-24 02:00PM
|
|
|
Mar-27-24 01:27AM
|
|
|
Mar-15-24 05:31AM
|
|
|
Mar-13-24 07:00AM
|
|
|
Feb-07-24 07:00AM
|
|
|
Jan-29-24 08:14AM
|
|
|
Jan-03-24 07:00AM
|
|
|
Dec-28-23 07:01AM
|
|
|
Nov-23-23 11:47AM
|
|
|
Nov-22-23 07:00AM
|
|
|
Nov-07-23 08:25AM
|
|
|
08:06AM
|
|
|
07:00AM
|
|
|
Oct-12-23 07:00AM
|
|
|
Sep-21-23 07:00AM
|
|
|
Sep-16-23 01:01AM
|
|
|
Sep-07-23 07:00AM
|
|
|
Aug-29-23 07:00AM
|
|
|
Aug-10-23 07:00AM
|
|
|
Aug-08-23 08:40AM
|
|
|
07:00AM
|
|
|
Aug-04-23 06:36AM
|
|
|
Aug-01-23 07:00AM
|
|
|
Jul-21-23 06:43AM
|
|
|
Jun-06-23 07:00AM
|
|
|
May-15-23 06:03AM
|
|
|
May-13-23 08:03AM
|
|
|
May-10-23 07:00AM
|
|
|
|
|
|
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV) therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The company's oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Entrada Therapeutics was founded by Dehua Pei in 2016 and is headquartered in Boston, MA. | |
|
|
|
| |
|
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| WENTWORTH KORY JAMES | Chief Financial Officer | Apr 01 '26 | Sale | 12.95 | 2,500 | 32,375 | 119,010 | Apr 02 04:39 PM | | KORY WENTWORTH | Officer | Apr 01 '26 | Proposed Sale | 12.62 | 2,500 | 31,550 | | Apr 01 04:38 PM | | Dowden Nathan J | President & COO | Mar 10 '26 | Sale | 13.05 | 11,894 | 155,188 | 198,588 | Mar 11 04:35 PM | | Dowden Nathan J | President & COO | Mar 09 '26 | Sale | 13.02 | 3,116 | 40,583 | 210,482 | Mar 11 04:35 PM | | WENTWORTH KORY JAMES | Chief Financial Officer | Mar 10 '26 | Sale | 13.02 | 11,388 | 148,216 | 121,510 | Mar 11 04:34 PM | | WENTWORTH KORY JAMES | Chief Financial Officer | Mar 09 '26 | Sale | 13.00 | 5,089 | 66,163 | 132,898 | Mar 11 04:34 PM | | KORY WENTWORTH | Officer | Mar 09 '26 | Proposed Sale | 12.58 | 16,477 | 207,281 | | Mar 09 04:37 PM | | NATHAN DOWDEN | Officer | Mar 09 '26 | Proposed Sale | 12.58 | 15,010 | 188,826 | | Mar 09 04:34 PM | | WENTWORTH KORY JAMES | Chief Financial Officer | Mar 04 '26 | Sale | 12.25 | 7,988 | 97,892 | 137,987 | Mar 06 04:36 PM | | KORY WENTWORTH | Officer | Mar 04 '26 | Proposed Sale | 11.85 | 7,988 | 94,658 | | Mar 04 05:11 PM | | WENTWORTH KORY JAMES | Chief Financial Officer | Nov 21 '25 | Sale | 9.98 | 8,910 | 88,932 | 110,026 | Nov 24 04:30 PM | | BAKER BROS. ADVISORS LP | 10% Owner | Nov 20 '25 | Buy | 9.07 | 28,867 | 261,846 | 4,691,392 | Nov 24 04:09 PM | | KORY WENTWORTH | Officer | Nov 21 '25 | Proposed Sale | 9.17 | 8,910 | 81,705 | | Nov 21 04:45 PM | | PARMAR KUSH | Director | Nov 14 '25 | Sale | 8.80 | 200,000 | 1,760,000 | 2,963,066 | Nov 18 04:36 PM | | 5AM Ventures V, L.P. | 10% Owner | Nov 14 '25 | Sale | 8.80 | 200,000 | 1,760,000 | 2,963,066 | Nov 18 04:34 PM | | 5AM Ventures V, L.P. | Affiliated Stockholder | Nov 14 '25 | Proposed Sale | 8.80 | 200,000 | 1,760,664 | | Nov 14 04:30 PM | | BAKER BROS. ADVISORS LP | 10% Owner | Nov 12 '25 | Buy | 7.76 | 100,736 | 781,638 | 4,664,924 | Nov 12 05:34 PM | | BAKER BROS. ADVISORS LP | 10% Owner | Nov 11 '25 | Buy | 7.50 | 46,434 | 348,193 | 4,572,549 | Nov 12 05:34 PM | | BAKER BROS. ADVISORS LP | 10% Owner | Nov 10 '25 | Buy | 7.21 | 30,874 | 222,756 | 4,529,969 | Nov 12 05:34 PM | | PARMAR KUSH | Director | Jul 09 '25 | Sale | 7.50 | 27,000 | 202,554 | 1,093,313 | Jul 11 05:27 PM | | 5AM Ventures V, L.P. | 10% Owner | Jul 09 '25 | Sale | 7.50 | 20,065 | 150,528 | 3,163,066 | Jul 11 05:25 PM | | 5AM Ventures V, L.P. | 10% Owner | Jul 09 '25 | Sale | 7.50 | 6,935 | 52,026 | 1,093,313 | Jul 11 05:25 PM | | 5AM Opportunities I, L.P. | Director | Jul 09 '25 | Proposed Sale | 7.50 | 6,935 | 52,025 | | Jul 09 05:04 PM | | 5AM Ventures V, L.P. | Director | Jul 09 '25 | Proposed Sale | 7.50 | 20,065 | 150,528 | | Jul 09 05:02 PM | | PARMAR KUSH | Director | Jun 27 '25 | Sale | 6.91 | 75,000 | 518,250 | 1,113,092 | Jul 01 08:33 PM | | PARMAR KUSH | Director | Jul 01 '25 | Sale | 7.12 | 25,000 | 178,065 | 1,100,248 | Jul 01 08:33 PM | | PARMAR KUSH | Director | Jun 30 '25 | Sale | 6.81 | 25,000 | 170,318 | 1,106,670 | Jul 01 08:33 PM | | 5AM Ventures V, L.P. | 10% Owner | Jun 27 '25 | Sale | 6.91 | 55,735 | 385,129 | 3,220,287 | Jul 01 08:32 PM | | 5AM Ventures V, L.P. | 10% Owner | Jun 27 '25 | Sale | 6.91 | 19,265 | 133,121 | 1,113,092 | Jul 01 08:32 PM | | 5AM Ventures V, L.P. | 10% Owner | Jul 01 '25 | Sale | 7.12 | 18,578 | 132,324 | 3,183,131 | Jul 01 08:32 PM | | 5AM Ventures V, L.P. | 10% Owner | Jun 30 '25 | Sale | 6.81 | 18,578 | 126,566 | 3,201,709 | Jul 01 08:32 PM | | 5AM Ventures V, L.P. | 10% Owner | Jul 01 '25 | Sale | 7.12 | 6,422 | 45,741 | 1,100,248 | Jul 01 08:32 PM | | 5AM Ventures V, L.P. | 10% Owner | Jun 30 '25 | Sale | 6.81 | 6,422 | 43,751 | 1,106,670 | Jul 01 08:32 PM | | 5AM Ventures V, L.P. | Director | Jul 01 '25 | Proposed Sale | 7.12 | 18,578 | 132,324 | | Jul 01 05:03 PM | | 5AM Opportunities I, L.P. | Director | Jul 01 '25 | Proposed Sale | 7.12 | 6,422 | 45,737 | | Jul 01 05:01 PM | | 5AM Opportunities I, L.P. | Director | Jun 30 '25 | Proposed Sale | 6.81 | 6,422 | 43,751 | | Jun 30 05:09 PM | | 5AM Ventures V, L.P. | Director | Jun 30 '25 | Proposed Sale | 6.81 | 18,578 | 126,566 | | Jun 30 05:06 PM | | 5AM Opportunities I, L.P. | Director | Jun 27 '25 | Proposed Sale | 6.91 | 19,265 | 133,121 | | Jun 27 05:05 PM | | 5AM Ventures V, L.P. | Director | Jun 27 '25 | Proposed Sale | 6.91 | 55,735 | 385,129 | | Jun 27 05:03 PM |
|
|
